
## Application No. 09/662,649 Attorney Docket No. 02481.1690

heteroarylcycloalkenyl, fused heteroarylcycloalkyl, fused heteroarylheterocyclenyl, or fused heteroarylheterocyclyl;

A is -O-, -S-, -SO-, -SO<sub>2</sub>-, -NR<sub>13</sub>-, -C(O)-, -N(R<sub>14</sub>)C(O)-, -C(O)N(R<sub>15</sub>)-, -N(R<sub>14</sub>)C(O)N(R<sub>15</sub>)-, -C(R<sub>14</sub>)=N-, a chemical bond,



B and E are a chemical bond?

a is 0-6;

b is 0-4;

c is 0;

d is 0:

g is 1-5;

h is 1-4;

R<sub>1</sub>, R<sub>3</sub>, R<sub>5</sub> and R<sub>7</sub>, are independently hydrogen, halogen, alkyl, carboxyl, alkoxycarbonyl or aralkyl;

 $R_2$ ,  $R_4$ ,  $R_6$  and  $R_8$ , are independently -(CH<sub>2</sub>)<sub>q</sub>-X

q is 0-3;

X is hydrogen, halogen, alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl, hydroxy, alkoxy, aralkoxy, heteroaralkoxy, carboxyl,

alkoxycarbonyl, tetrazolyl, acyl, acylHNSO<sub>2</sub>-, -SR<sub>23</sub>,  $\chi^1 \chi^2 N$ - or  $\chi^3 \chi^4 NCO$ -;

 $Y^1$  and  $Y^2$  are independently hydrogen, alkyl, aryl, aralkyl or heteroaralkyl, or one of  $Y^1$  and  $Y^2$  is hydrogen or alkyl and the other of  $Y^1$  and  $Y^2$  is acyl or aroyl;  $Y^3$  and  $Y^4$  are independently hydrogen, alkyl, aryl, aralkyl or heteroaralkyl;





## **Application No. 09/662,649 Attorney Docket No. 02481.1690**

Z is  $R_2 O_2 C_7$ ,  $R_{21} O C_7$ , cyclo-imide, -CN,  $R_{21} O_2 SHNCO_7$ ,  $R_{21} O_2 SHNCO_7$ ,  $R_{21} O_3 SHNCO_7$ ,  $R_{21} O_4 SHNCO_7$ , ox 2,4-thiazolidinedionyl; and

R<sub>21</sub> is independently hydrogen, alkyl, aryl, cycloalkyl, or aralkyl;

R<sub>13</sub> and R<sub>23</sub> are independently R<sub>22</sub>OC-, R<sub>22</sub>NHOC-, hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, heteroaralkyl, or aralkyl;

R<sub>14</sub>, R<sub>15</sub>, R<sub>16</sub> are independently hydrogen, alkyl, aralkyl, carbonyl, or alkoxycarbonyl; or R<sub>14</sub>, and R<sub>15</sub> taken together with the carbon and nitrogen atoms through which they are linked form a 5 or 6-membered azaheterocyclyl group; or when a is 2-6, then at least one pair of vicinal R<sub>1</sub> radicals taken together with the

Be

carbon atoms to which the R<sub>1</sub> radicals are linked form a R<sub>2</sub> group; or when b is 2-4, then at least one pair of vicinal R<sub>3</sub> radicals taken together with the

R<sub>4</sub> Yú


carbon atoms to which the  $R_3$  radicals are linked form a  $R_4$  group; or geminal  $R_5$  and  $R_6$  radicals taken together with the carbon atom through which these radicals are linked form a 5 membered cycloalkyl group; or geminal  $R_7$  and  $R_8$  radicals taken together with the carbon atom through which these radicals are linked form a 5 membered cycloalkyl group; and  $R_{22}$  is hydrogen, alkyl, aryl, heteroaryl, cycloalkyl, heterocyclyl, heteroaralkyl, or aralkyl; or

a pharmaceutically acceptable salt thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof.

B5 Cont 55. (Amended) A method according to claim 54 wherein the disease is associated with a physiological detrimental blood level of insulin, glucose, free fatty acids, or triglycerides.



## 97. (New) A compound as claimed in claim 1, which is of formula



Bark O.6

wherein

(Ar I

is optionally substituted heteroaryl;

a = 1;

b = 0;

R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub>, R<sub>4</sub> are hydrogen

$$--$$
0 $\xrightarrow{R_{15}}$ 0 $\xrightarrow{}$ 

A is

R<sub>5</sub>, R<sub>6</sub>, R<sub>7</sub>, R<sub>8</sub>, R<sub>15</sub>, R<sub>16</sub> are hydrogen;

c = 0;

d = 0;

g = 2, 3, 4 or 5;

B and E are a chemical bond;

 $Z \text{ is } R_{21}O_2C$ -,  $R_{21}OC$ -, or  $R_{21}O$ -;

R<sub>21</sub> is hydrogen, alkyl, aryl, cycloalkyl, or aralkyl;

R' is hydrogen, lower alkyl, halo, alkoxy, aryloxy or aralkyloxy, and

R" is lower alkyl, hydrogen, aralkyloxy, alkoxy, cycloalkylalkyloxy or halo, or